What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Immune system
Stephen Gottschalk spends much of his time researching Immunology, Antigen, Immunotherapy, Cytotoxic T cell and Adoptive cell transfer.
The various areas that he examines in his Immunology study include Hematopoietic stem cell transplantation and Virology.
Stephen Gottschalk combines subjects such as Cancer research, Oncology, Virus, Internal medicine and Chimeric antigen receptor with his study of Antigen.
His biological study deals with issues like Pathology, which deal with fields such as Stem cell.
His study in Antigen-presenting cell and CTL* is done as part of Cytotoxic T cell.
Stephen Gottschalk has included themes like ELISPOT and Interleukin 21 in his Adoptive cell transfer study.
His most cited work include:
- Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma (500 citations)
- Post-transplant lymphoproliferative disorders. (427 citations)
- Design and development of therapies using chimeric antigen receptor-expressing T cells (365 citations)
What are the main themes of his work throughout his whole career to date?
Stephen Gottschalk focuses on Immunology, Antigen, Immunotherapy, Cancer research and Cytotoxic T cell.
In his study, Oncology is strongly linked to Hematopoietic stem cell transplantation, which falls under the umbrella field of Immunology.
His Antigen research incorporates elements of T cell, Molecular biology and Virus, Virology.
His Immunotherapy research integrates issues from Epitope, Adoptive cell transfer and Chemotherapy.
His Cancer research research includes themes of Receptor and Tumor antigen.
His studies deal with areas such as Epstein–Barr virus, Cancer immunotherapy and Lymphoma as well as Cytotoxic T cell.
He most often published in these fields:
- Immunology (57.40%)
- Antigen (43.32%)
- Immunotherapy (36.82%)
What were the highlights of his more recent work (between 2015-2021)?
- Cancer research (34.30%)
- Immunology (57.40%)
- Antigen (43.32%)
In recent papers he was focusing on the following fields of study:
Stephen Gottschalk mainly investigates Cancer research, Immunology, Antigen, Chimeric antigen receptor and Immunotherapy.
His Cancer research study combines topics in areas such as Car t cells and Antibody.
The Immunology study combines topics in areas such as Hematopoietic stem cell transplantation, Stem cell and Genetically modified organism.
His research ties PRAME and Antigen together.
The concepts of his Chimeric antigen receptor study are interwoven with issues in Cytokine, Virology, A549 cell, Cytotoxic T cell and Glioblastoma.
His Immunotherapy research focuses on subjects like Receptor, which are linked to Chemotherapy.
Between 2015 and 2021, his most popular works were:
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. (269 citations)
- HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial (249 citations)
- Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants. (101 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Immune system
Chimeric antigen receptor, Immunology, Cancer research, Immunotherapy and Cytotoxic T cell are his primary areas of study.
The Chimeric antigen receptor study which covers Cytokine that intersects with Adoptive cell transfer.
His research investigates the connection between Immunology and topics such as A549 cell that intersect with issues in Adenoviridae and Leukemia.
His Cancer research study frequently draws parallels with other fields, such as Antigen.
His work deals with themes such as Receptor, Oncology and T cell, which intersect with Antigen.
His Immunotherapy study is concerned with the larger field of Cancer.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
